Edwards Lifesciences (NYSE:EW) VP Sells $56,576.60 in Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 619 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $91.40, for a total value of $56,576.60. Following the completion of the sale, the vice president directly owned 40,411 shares of the company’s stock, valued at approximately $3,693,565.40. This represents a 1.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Stock Down 0.8%

NYSE EW traded down $0.71 on Tuesday, hitting $90.47. 3,609,561 shares of the stock traded hands, compared to its average volume of 4,861,138. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The stock has a 50-day moving average of $84.66 and a 200 day moving average of $83.31. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $92.88. The company has a market capitalization of $52.09 billion, a P/E ratio of 48.12, a price-to-earnings-growth ratio of 2.29 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business’s revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Institutional Trading of Edwards Lifesciences

Several large investors have recently added to or reduced their stakes in the business. Level Four Advisory Services LLC increased its position in Edwards Lifesciences by 3.7% in the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock valued at $257,000 after acquiring an additional 119 shares during the period. Evermay Wealth Management LLC lifted its holdings in shares of Edwards Lifesciences by 4.0% during the fourth quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company’s stock worth $282,000 after purchasing an additional 128 shares during the period. Rehmann Capital Advisory Group lifted its holdings in shares of Edwards Lifesciences by 2.1% during the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock worth $546,000 after purchasing an additional 130 shares during the period. Florida Trust Wealth Management Co grew its stake in shares of Edwards Lifesciences by 1.5% in the fourth quarter. Florida Trust Wealth Management Co now owns 8,810 shares of the medical research company’s stock worth $751,000 after purchasing an additional 132 shares during the last quarter. Finally, McIlrath & Eck LLC grew its stake in shares of Edwards Lifesciences by 14.6% in the fourth quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock worth $90,000 after purchasing an additional 135 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Barclays restated an “overweight” rating and issued a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Robert W. Baird increased their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Canaccord Genuity Group set a $85.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Finally, TD Cowen restated a “buy” rating and issued a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a research note on Tuesday, June 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $96.39.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.